Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

The promise of antiangiogenic therapy for ovarian cancer.

Jazaeri AA, Slack-Davis JK.

Cancer Biol Ther. 2009 Dec;8(23):2273-4. Epub 2009 Dec 25. No abstract available.

PMID:
19907207
2.

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK.

Cancer Biol Ther. 2009 Dec;8(23):2263-72. Epub 2009 Dec 19.

3.

Development of antiangiogenic therapies for ovarian cancer.

Markowska A, Lubin J, Madry R, Markowska J.

Eur J Gynaecol Oncol. 2013;34(4):303-6.

PMID:
24020134
4.
5.

Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed.

González Martín A.

Clin Transl Oncol. 2009 Sep;11(9):559-60. No abstract available.

PMID:
19775993
6.

FAS1 domain protein inhibits VEGF165-induced angiogenesis by targeting the interaction between VEGFR-2 and αvβ3 integrin.

Nam JO, Son HN, Jun E, Cha K, Lee BH, Park RW, Kim IS.

Mol Cancer Res. 2012 Aug;10(8):1010-20. doi: 10.1158/1541-7786.MCR-11-0600. Epub 2012 Jun 18.

7.

Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.

van der Bilt AR, de Vries EG, de Jong S, Timmer-Bosscha H, van der Zee AG, Reyners AK.

Crit Rev Oncol Hematol. 2012 Nov;84(2):224-42. doi: 10.1016/j.critrevonc.2012.03.006. Epub 2012 Apr 21. Review.

PMID:
22525643
8.

Multitargeting ovarian epithelial cancer: adding the old to the new.

Garfield DH.

J Clin Oncol. 2008 Mar 20;26(9):1565-6. doi: 10.1200/JCO.2007.15.6448. No abstract available.

PMID:
18349413
9.

Blocking αvβ3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells.

Montenegro CF, Salla-Pontes CL, Ribeiro JU, Machado AZ, Ramos RF, Figueiredo CC, Morandi V, Selistre-de-Araujo HS.

Biochimie. 2012 Aug;94(8):1812-20. doi: 10.1016/j.biochi.2012.04.020. Epub 2012 Apr 27.

10.

The future of targeted therapies in ovarian cancer.

Banerjee S, Gore M.

Oncologist. 2009 Jul;14(7):706-16. doi: 10.1634/theoncologist.2009-0013. Epub 2009 Jul 10. Review.

11.

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

Kumar CC.

Curr Drug Targets. 2003 Feb;4(2):123-31. Review.

PMID:
12558065
12.

alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment.

Hodivala-Dilke K.

Curr Opin Cell Biol. 2008 Oct;20(5):514-9. doi: 10.1016/j.ceb.2008.06.007. Epub 2008 Aug 6. Review.

PMID:
18638550
13.

Effects of integrins and integrin αvβ3 inhibitor on angiogenesis in cerebral ischemic stroke.

Bi JJ, Yi L.

J Huazhong Univ Sci Technolog Med Sci. 2014 Jun;34(3):299-305. doi: 10.1007/s11596-014-1274-4. Epub 2014 Jun 18. Review.

PMID:
24939290
14.

Angiogenesis as a strategic target for ovarian cancer therapy.

Spannuth WA, Sood AK, Coleman RL.

Nat Clin Pract Oncol. 2008 Apr;5(4):194-204. doi: 10.1038/ncponc1051. Epub 2008 Feb 12. Review.

PMID:
18268546
15.

Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac).

Yoshida T, Gong J, Xu Z, Wei Y, Duh EJ.

Exp Eye Res. 2012 Jan;94(1):41-8. doi: 10.1016/j.exer.2011.11.003. Epub 2011 Nov 19.

16.

Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.

Holtz DO, Krafty RT, Mohamed-Hadley A, Zhang L, Alagkiozidis I, Leiby B, Guo W, Gimotty PA, Coukos G.

J Transl Med. 2008 Jan 8;6:2. doi: 10.1186/1479-5876-6-2.

17.

Noninvasive tracer techniques to characterize angiogenesis.

Haubner R.

Handb Exp Pharmacol. 2008;(185 Pt 2):323-39. doi: 10.1007/978-3-540-77496-9_14. Review.

PMID:
18626609
18.

SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.

Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE.

Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.

PMID:
16565398
19.

Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor.

Li W, Xu RJ, Lin ZY, Zhuo GC, Zhang HH.

Med Oncol. 2009;26(2):170-7. doi: 10.1007/s12032-008-9104-9. Epub 2008 Nov 6.

PMID:
18988002
20.

Ovarian cancer and antiangiogenic therapy: caveat emptor.

Oliver KE, McGuire WP.

J Clin Oncol. 2014 Oct 20;32(30):3353-6. doi: 10.1200/JCO.2014.57.4574. Epub 2014 Sep 15. No abstract available.

PMID:
25225422

Supplemental Content

Support Center